

# Index

## A

ACACA. *See* Acetyl-CoA carboxylase  
Acetyl-CoA carboxylase (ACACA), 216  
AKT, 30, 214, 329, 359, 382–383  
Alanine transaminase, 247  
ALK, 363, 365  
ALT, 364  
ALV. *See* Avian leukosis virus  
AMPK, 218, 397  
Angiogenesis  
    microRNA role and MYC interactions  
        let-7, 140  
        miR-9, 139–140  
        miR-17–92, 141–142  
        miR-200, 140–141  
        overview, 139  
    neuroblastoma and MYCN, 356  
APAF1, 261  
APC, 198  
Apoptosis  
    microRNA regulation and MYC interactions  
        miR-15a, 136–137  
        miR-16, 136–137  
        miR-17–92, 136  
        miR-34, 137  
        overview, 135  
    MYC role  
        activation levels as determinant of apoptotic potential, 260  
        BAG-1 modulation, 260  
        CL-2 in evasion, 259–260  
        history of study, 257–259  
        induction, 35–36  
        MYC-synthetic lethal genes and cancer, 397–398  
        overview, 35–36  
        p53 modulation, 260–262  
        prospects for study, 263  
    neuroblastoma and MYCN, 357–358  
    TXNIP role, 251–252  
ARE, 30–31, 35–36, 39–41, 97, 135, 261  
ARID1A, 364  
ARID1B, 364  
ARK5, 218, 236, 397, 400  
ARRDC4, 247, 252  
ASCT2, 211  
ASH2/ANCCA, 28, 52  
Aspartate aminotransferase, 247

ATAD2, 395  
ATF4, 251–252  
ATM, 276  
ATM, 294, 296–297  
ATR, 276–277, 296–297, 397  
ATRX, 363–364  
AURKA. *See* Aurora kinase A  
Aurora kinase A (AURKA), 362, 415  
Avian leukosis virus (ALV), 2

## B

BAG-1, 260  
BAK, 261  
BARD1, 395  
BAX, 261  
B cell, transcriptional activity, 68–69  
B-cell receptor (BCR), 329–330  
BCL-2, 35–36, 94–95, 135–137, 259–260, 309, 357  
BCR. *See* B-cell receptor  
BCR-ABL, 311  
 $\beta$ -Catenin, 337, 377, 414  
 $\beta$ -TrCP, 105  
Bim, 135  
BL. *See* Burkitt lymphoma  
BMI1, 356–357  
BMP. *See* Bone morphogenetic protein  
BMP-4, 171  
Bone morphogenetic protein (BMP), cell competition signaling, 200–201  
BPTES, 219, 251  
BRAF, 311  
Brat, 188  
BRCA, 389  
BRCA1, 297, 364, 398  
BRD2, 361, 411  
BRD3, 411  
BRD4, 37, 82–83, 345, 392–393, 411  
Brl1, 124  
Brinker, 187  
Brk, 200  
Burkitt lymphoma (BL)  
    epidemiology of endemic disease, 322–323  
    gene mutations, 324–328  
    germinal center reaction in development, 323–324  
    oncogenic signaling pathways, 328–330  
    overview, 321–322  
    therapeutic targets, 330–331

## Index

### C

CAD, 80–81, 273  
Caspase-8, 355  
CBP/P300, 410, 415  
CCND2, 81  
Cdc25A, 132  
Cdc45, 290, 292–293, 299  
CDK1, 361, 397  
CDK12, 395  
CDK1B, 248, 254  
CDK2, 37, 358, 397  
Cdk2, 288–289, 293–295, 299  
CDK4, 357  
CDK5, 37  
CDK7, 413  
CDK8, 413  
CDK9, 395, 411, 413  
CDKL5, 356  
CDKN1A, 94  
CDKN1C, 84  
CDKN2A, 326  
CDKN2B, 94  
CECR2, 395, 398, 400  
Cell competition  
  cancer role, 203–204  
  conservation, 194, 196  
  development role, 203–204  
  genetic heterogeneity elimination, 194  
  hallmarks, 194–195  
  metabolism role, 198–200  
  mutations in mosaics, 195  
  overview, 193–194  
  prospects for study, 204  
  ribosome biogenesis and protein synthesis role, 198  
  signaling of fitness differences  
    Decapentaplegic, 200–201  
    Flower, 203  
    Hippo, 202–203  
    transforming growth factor- $\beta$ /bone  
      morphogenetic protein  
  super competitor genes  
    MYC, 197–198  
    overview, 196–197  
Cell cycle. *See* Cell growth; DNA replication  
Cell growth  
  bioenergetics, 210–213  
  MYC  
    cancer deregulation and therapeutic  
      targeting, 219  
    fatty acid synthesis regulation, 216  
    glutaminolysis regulation, 214–215  
    glycolysis regulation, 213–214  
    mitochondrial biogenesis regulation.  
      *See* Mitochondria  
    MYC-synthetic lethal genes and cancer, 397–398

  nucleotide synthesis regulation, 215  
  prospects for study, 219–220  
  S phase entry regulation, 218–219  
  transcriptional regulation, 213  
    neuroblastoma and MYCN, 357–359  
CHIP, 107, 110  
CHK1, 277, 294, 358  
CHK2, 277, 294  
ChREBP  
  glucose regulation, 244  
  MLX interactions, 9, 13, 244  
  tissue distribution, 243–244  
CIITA, 83  
CIP2A, 37, 111  
CLIC4, 225  
c-Myb, 143–144  
c-myc. *See* MYC  
Colon cancer, MIZ-1 mouse model, 95–97  
CoREST complex, 172  
CpG island, MYC binding sites, 51  
CSMD1, 364  
CSNK1e, 398, 400, 415  
CT element, 72, 74  
CTCF, 377–378  
CTGF, 141  
CUL7, 357  
Cyclin D1, 359  
Cyclin D2, 274, 288  
Cyclin D3, 325–326, 328–330  
Cyclin E, 288–289, 296  
Cytidine deaminase, 322

### D

Dbf4-dependent kinase (DDK), 290, 292  
Dbp11, 291  
DDK. *See* Dbf4-dependent kinase  
DDR. *See* DNA damage response  
DDX8, 185  
DDX18, 397  
Decapentaplegic (Dpp), 184, 187, 200–201  
Development. *See* *Drosophila* Myc; Vertebrate  
  development, MYC function  
DHFR. *See* Dihydrofolate reductase  
Dicer, 131  
Dihydrofolate reductase (DHFR), 268–270, 273–274  
*Diminutive*. *See* *Drosophila* Myc  
Dlg, 202  
dMyc. *See* *Drosophila* Myc  
DNA damage response (DDR)  
  DNA repair  
    MYC-synthetic lethal genes and cancer,  
      396–397  
    overview, 276–277  
  genomic instability and MYC, 274–276  
  replication stress, 294

- DNA methyltransferase (DNMT), MIZ-1 interactions, 39
- DNA replication
- G<sub>1</sub>/S transition control by MYC
  - cyclin E/Cdk2 role, 288–289
  - overview, 287
  - transcriptional control of cell cycle entry, 288
- genomic instability and MYC, 273–274, 298–299
- initiation
- MYC role, 293
  - nontranscriptional control, 289–290
  - origin assembly and activation mechanism, 289–292
  - replication timing and origin selection, 292–293
- prospects for study, 299–300
- replication stress and MYC
- inducers, 295
  - overview, 275, 293–294
  - preneoplasia, 294–295
  - protection
    - ATM, 296–297
    - ATR, 296–297
    - BRCA1, 297
    - nucleotides, 297–298
    - WRN, 295–297
- DNMT. *See* DNA methyltransferase
- Dpp. *See* Decapentaplegic
- DREF, 183
- Drosophila Myc* (dMyc)
- blood cell studies, 184
  - body size regulation, 180
  - cell competition studies. *See* Cell competition
  - expression regulation
    - Dpp, 187
    - EcR, 188–189
    - Hpo, 187–188
    - overview, 186
    - target of rapamycin, 188
    - Wg, 186–187
- functional overview, 179–180
- imaginal disc function, 180–182
- polyploid tissue activity, 182–183
- ribosome biogenesis role, 118, 181, 185
- stem cell studies, 183–184
- transcriptional targets, 184–186
- DSIF, 81–82
- E**
- E2A. *See* TCF-3
- E2F, 130–131, 134, 218–219, 226
- E2F1, 174, 296
- EBNA1, 323
- EBV. *See* Epstein–Barr virus
- EcR, 188–189
- EE. *See* Extrachromosomal element
- EGFR. *See* Epidermal growth factor receptor
- EGR, MYC target genes, 31, 35–36
- eIF4E2, 398
- EMT. *See* Epithelial-to-mesenchymal transition
- ENCODE project, 49–50, 52, 56, 379
- Epidermal growth factor receptor (EGFR), 311
- Epigenetics
- medulloblastoma, 343–344
  - neuroblastoma and MYCN, 359
- Epithelial-to-mesenchymal transition (EMT), 139–141, 355
- Epstein–Barr virus (EBV), 323
- Estrogen receptor, 118, 120, 122
- Estrogen-related receptors, 226, 234
- Extrachromosomal element (EE), MYC induction, 271
- EZH2, 382–383
- F**
- FACT, 82
- FAK, 354
- FBW7, 37, 103–104, 361, 407–408
- Fbx29, 107
- FBXW7, 396, 415
- Fkh1, 292
- Fkh2, 292
- Flower (Fwe), 293
- FoxO, 81, 237
- FUSE, 73–74
- Fwe. *See* Flower
- G**
- GATA6, 171–172
- GCN5, 27–28, 37, 64, 407, 410, 415
- Gdown1, 81
- Genomic instability
- DNA repair, 276–277
  - MYC role
    - dihydrofolate reductase amplification, 268–270
    - DNA damage, 274–276
    - DNA replication, 273–274
    - extrachromosomal elements, 271
    - history of study, 267–268
    - karyotypic instability, 271
    - Myc box mutants, 273
    - nuclear remodeling, 277
    - p53 deficiency effects, 271–273
    - prospects for study, 277s–278
    - replication stress, 275–276, 298–299
    - target genes in instability induction, 270–271
    - transforming activity, 268
- Germinal center. *See* Burkitt lymphoma

## Index

- Gfi-1, 95  
GFPT1, 243  
GINs complex, 290, 292–293  
Glutaminase, 219  
Glutamine  
    MYC and glutaminolysis regulation, 214–215  
    restriction and apoptosis, 251–252  
GLUTs, 137, 199  
GSK-3 $\beta$ , 135, 171, 188, 361, 415  
GTF2H4, 393
- H**
- HATs. *See* Histone acetyltransferases  
Hay/XBP, 186  
HCK, 398  
HDACs. *See* Histone deacetylases  
HectH9, 106, 110  
Hematopoiesis, microRNA role and MYC interactions  
    miR-17–92, 144–145  
    miR-150, 143–144  
Hfp, 186  
Hippo, cell competition signaling, 202–203  
Histone acetyltransferases (HATs)  
    MYC interactions, 27, 30  
    MYC ubiquitination interactions, 108  
Histone deacetylases (HDACs), 361  
    inhibition, 414  
    medulloblastoma, 345  
    mSin3 interactions, 10  
    MYC in recruitment, 30–31, 38–39, 52  
    tumor activity, 37–38  
HMGA2, 140  
Hpo, 187–188
- I**
- ID1*, 328  
*ID2*, 328  
*ID2*, 130, 358  
*ID3*, 328  
IIS, 188
- J**
- JAK, 198  
JARID, 248  
JARID1A, 26, 413–414  
JNK, 203
- K**
- KLF2, 356  
Klf4 (OSK), 51, 141, 174–175, 356, 414–415  
KRAS2, 268  
Ku70, 275
- L**
- Lactate dehydrogenase (LDH), 211, 219  
Lamin B2, 274  
LDH. *See* Lactate dehydrogenase  
LDHA, 137–138  
LEF-1, 376, 378  
Let-7, 134, 140  
Leukemia inhibitory factor (LIF), 170–173, 356  
Lgl, 202–203  
LIF. *See* Leukemia inhibitory factor  
LIN28B, 140, 364  
L-myc. *See* MYCL1  
LSD1, 172  
Lymphoma. *See also* Burkitt lymphoma  
    microRNA role, 143–145  
    MIZ-1 mouse model, 96
- M**
- MAD. *See* MXD proteins  
Mammalian target of rapamycin (mTOR), 185, 188,  
    211–212, 245, 356  
MAPK. *See* Mitogen-activated protein kinase  
MAX  
    DNA binding modes, 53–55  
    *Drosophila*, 179–180, 185  
    evolution of network, 14–16  
    homodimerization, 6  
    MGA interactions, 9  
    MXD interactions, 6, 9  
    MYC interactions, 4–6, 26, 53–55, 64, 80, 154–155  
    PC12 cell  
    protein organization, 5  
MCM, 131, 290–292  
MCP-1, 355  
MCR, 245  
MDM, 35  
MDM2, 261, 357, 362, 397  
Mdm2, 135, 137, 212  
Medulloblastoma  
    epigenetics, 343–344  
    microRNA  
        MYC regulation, 344  
        regulation by MYC, 344–345  
    overview, 335–337  
    posterior fossa development role of MYC, 341–343  
    prospects for study, 346  
    subgroups and MYC involvement  
        group 3 subgroup, 339–340  
        group 4 subgroup, 340–341  
        SHH subgroup, 337–339  
        WNT subgroup, 337  
    therapeutic targets, 345–346  
Mei-P26  
Metabolism. *See* Cell competition; Cell growth;  
    MicroRNA; Mitochondria

- Metastasis
  - microRNA role and MYC interactions
    - let-7, 140
    - miR-9, 139–140
    - miR-17–92, 141–142
    - miR-200, 140–142
    - overview, 139
  - neuroblastoma and MYCN, 354–355
- Methotrexate, 268, 270
- MGA
  - MAX interactions, 9
  - mutation in cancer, 12
- MicroRNA
  - apoptosis regulation and MYC interactions
    - miR-15a, 136–137
    - miR-16, 136–137
    - miR-17–92, 136
    - miR-34, 137
    - overview, 135
  - cell cycle regulation and MYC interactions
    - let-7, 134
    - miR-15a, 134
    - miR-16, 134
    - miR-17–92, 134–135
    - miR-26, 134
    - miR-34, 133
  - E2F targeting, 218–219
  - hematopoiesis role and MYC interactions
    - miR-17–92, 144–145
    - miR-150, 143–144
  - medulloblastoma microRNA
    - MYC regulation, 344
    - regulation by MYC, 344–345
  - messenger RNA complementarity, 131
  - metabolism regulation and MYC interactions
    - miR-17–92, 138
    - miR-23, 138–139
    - overview, 137–138
  - metastasis and angiogenesis roles and MYC interactions
    - interactions
      - let-7, 140
      - miR-9, 139–140
      - miR-17–92, 141–142
      - miR-200, 140–142
      - overview, 139
    - pluripotency role and MYC interactions
      - miR-17–92, 143
      - miR-34, 143
      - miR-100, 142–143
      - miR-141, 142
      - miR-200, 142
      - miR-290, 141–142
      - miR-371, 142–143
      - miR-429, 200
      - overview, 141–142
      - prospects for study, 145
  - Minute*, 194, 196–198, 200
  - Mitochondria
    - biogenesis overview, 225–227, 234
    - MYC in biogenesis
      - cell cycle entry and biogenesis stimulation, 235
      - mass regulation, 234–235
      - metabolism regulation, 237–238
      - nuclear-encoded mitochondrial gene targets, 228–234
      - overexpression studies, 235–236
      - overview, 216–218
      - prospects for study, 236–237
  - Mitogen-activated protein kinase (MAPK), stem cell signaling, 171–172
  - MIZ-1
    - DNA methyltransferase interactions, 39
    - MYC interactions
      - mouse models
        - colon cancer, 95–97
        - lymphoma, 96
        - normal development, 95
        - overview, 94–95
        - skin papilloma, 96
        - tumor models, 95–97
      - overview, 30, 36, 53, 91–93
      - prospects for study, 98
      - signaling, 97–98
      - target genes, 93–94
      - transcriptional repression, 93
  - Miz1, 293
  - MLH1, 276
  - MLL1, 292
  - MLL2*, 343
  - MLL3*, 343
  - MLX
    - ChREBP interactions. *See* ChREBP
    - cross talk among network members, 13–14
    - evolution of network, 14–16
    - MondoA interactions. *See* MondoA
    - protein interactions, 9, 12–13, 26
    - TXNIP feedback loop. *See* TXNIP
  - MLXIP, 242
  - MMP2, 354
  - MNT, 396
    - Drosophila*, 180
    - knockout mouse, 12
    - MYC antagonism, 12
    - protein organization, 5
  - MondoA
    - functional overview, 242
    - glucose regulation, 244–245
    - MLX interactions, 9, 13, 242–244
    - structure, 242
    - tissue distribution, 243–244
    - TXNIP feedback loop. *See* TXNIP
  - MondoB. *See* ChREBP

## Index

- MSH2, 276
- mSin3, MXD interactions, 9–10
- MTCL, knockout mouse, 157
- mTOR. *See* Mammalian target of rapamycin
- mTORC1, 397
- MUS81, 296
- MXD proteins
  - differentiation termination, 11
  - expression regulation, 10–11
  - knockout mouse, 11
  - MAX interactions, 6, 9, 26
  - MLX interactions, 12–13
  - mSin3 interactions, 9–10
  - MXD2 and tumor suppression, 12
  - MYC antagonism, 10
- MYBL2, 359
- MYC (*c-myc*)
  - expression regulation
    - DNA structure as sensor of activity, 71–74
    - locus characteristics, 78–79
    - overview, 10–11, 69–70
  - retroviral origins, 1
  - tumorigenesis overview, 2–3, 36–39
- MYC
  - apoptosis control. *See* Apoptosis
  - canonical transactivation regulation
    - chromatin remodeling, 28
    - chromatin-modifying enzymes, 26–27
    - MAX, 26
    - postranslational modification, 29–30
    - RNA polymerase, 28–29
  - cell competition studies. *See* Cell competition
  - cell growth transcription regulation. *See* Cell growth
  - cell proliferation role, 33–35
  - cofactor switch model, 40–41
  - cross talk among network members, 13–14
  - degradation
    - calpain-dependent cleavage, 102
    - overview, 102
    - prospects for study, 111–112
    - proteasomes, 102–103
    - ubiquitination
      - acetylation interplay, 108
      - regulators, 103–108
      - stability in cancer, 109–111
      - transcriptional activation linkage, 109
  - development. *See* *Drosophila* Myc; Vertebrate development, MYC function
  - DNA replication control. *See* DNA replication *Drosophila*. *See* *Drosophila* Myc
  - functional overview, 6–8, 64–67, 209–210
  - genome interactions
    - DNA binding modes, 53–55, 64
    - integrated view, 53–55
    - overview, 49–50
    - prospects for study, 56–57
    - transcription factor interactions, 50–53
    - transcriptional control implications, 55–56
  - genomic instability induction. *See* Genomic instability
  - MAX interactions, 4–6, 26, 53–55, 64, 80, 154–155
  - microRNA regulation. *See* MicroRNA
  - MIZ-1 interactions. *See* MIZ-1
  - MNT antagonism, 12
  - MXD antagonism, 10
  - noncanonical transcription regulation
    - target gene repression, 30–31
    - transactivation, 31
  - pluripotency establishment and maintenance.
    - See* Pluripotency
  - protein organization, 3–5
  - target genes, 31–32
  - therapeutic targeting
    - direct inhibitor development, 406–410
    - overview, 405–406
    - prospects, 416
    - stability targeting, 414–415
    - synthetic lethal screens for discovery, 400–401, 415–416
    - transcriptional signaling, 410–414
    - upstream pathways, 414s
  - transactivation domain, 6, 101, 103, 109
  - transcription elongation
    - overview, 79–81
    - general control factors, 81–82
    - recruitment of control factors, 82–83
    - oncogene alteration of gene expression programs, 83–84
    - transcriptional amplification, 84–86
  - tumorigenesis. *See also specific cancers*
    - distal regulation of MYC, 374–378
    - expression and cancer risk, 378–380
    - histone methylation at MTC-repressed genes, 380–381
    - immune response, 313–314
    - inherited predisposition to cancer, 375
    - initiation, 308–310
    - MYC-mediated repression, 379–380, 382–383
    - MYC suppression and reversal, 312–313
    - oncogenes in MYC-induced tumors, 310–312, 314
    - overview, 2–3, 36–39, 307–308, 373–374
    - prospects for study, 314–315, 383
    - PTEN activation, 381–382
    - synthetic lethal screen studies. *See* Synthetic lethal screen
- MYC boxes
  - box II
    - mutation and genomic instability, 273
    - therapeutic targeting, 410
  - functional overview, 6–7, 101
- MYCER, 269, 275, 388, 390

- MYCL  
 neuroblastoma role, 359–360  
 pluripotency role, 174
- MYCL1  
 medulloblastoma expression, 337, 339  
 tumorigenesis overview, 2, 85–86
- MYCL1, protein organization, 3–5
- MYCN  
 medulloblastoma expression, 337–339, 341–343  
 tumorigenesis overview, 2, 85–86
- MYCN  
 developmental disorders, 162  
 dose-dependent control of embryonic development, 155–158
- MYC  
 comparison, 351–354  
 coordinated action in lineage development and proliferative expansion, 158–160, 169–170  
 neuroblastoma role  
   angiogenesis, 356  
   apoptosis, 357–358  
   epigenetics, 359  
   immune surveillance, 355–356  
   metastasis, 354–355  
   pluripotency and self-renewal, 356–357  
   proliferation and cell cycle, 358–359  
 protein organization, 3–5
- N**
- N-myc*. *See* MYCN
- Nanog, 172, 356
- NCOR1, 392, 396
- NEDD4, 107
- NEIL, 397
- NELE, 81–82
- NEMO, 107–108
- Neuroblastoma  
 driver mutations  
   ALK, 363  
   ATRX, 363–364  
   candidate genes, 364  
 MYC role, 359–360  
 MYCL role, 359–360  
 MYCN role  
   angiogenesis, 356  
   apoptosis, 357–358  
   epigenetics, 359  
   immune surveillance, 355–356  
   metastasis, 354–355  
   pluripotency and self-renewal, 356–357  
   proliferation and cell cycle, 358–359  
 prospects for study, 365  
 risk classification, 351  
 therapeutic targets  
   BET bromodomain protein inhibitors, 361  
   differentiation inducers, 362  
   histone deacetylase, 361  
   MDM2, 362  
   MYC stability targets, 361–362  
   overview, 360–361
- NHEJ. *See* Nonhomologous end-joining
- NIPPED-B, 162
- Nol12, 185
- Nonhomologous end-joining (NHEJ), 275
- NOTCH1, 407, 414
- NPM, 34, 37–38
- NRF-1, 226–227, 234
- NRF-2, 226
- Nuclear factor- $\kappa$ B (NF- $\kappa$ B), 83
- NUP98, 413
- NuRD complex, 172
- O**
- Oct4, 81, 141, 172, 174–174, 356
- ODZ3, 364
- ORC. *See* Origin recognition complex
- Origin recognition complex (ORC), 289, 291
- Ornithine decarboxylase, 270
- OSK. *See* Klf4
- OSKM, 174–175
- P**
- p21, 143
- p27kip, 288–289, 342
- P300, 413
- p400, 35
- p53, 35–36, 129, 135, 143, 200, 204, 212, 260–262, 271–273, 294, 297, 309, 311, 324, 339–340, 357–358, 360, 397
- PARP, 389
- PATCHED*, 339, 342–343
- PCT. *See* Plasmacytoma
- PDH. *See* Pyruvate dehydrogenase
- PES1, 398, 400
- PGC-1 $\beta$ , 217, 227, 234
- PHGDH. *See* Phosphoglycerate dehydrogenase
- PHLPP2, 145
- Phosphoglycerate dehydrogenase (PHGDH), 215
- PI3K, 322–323, 329–330, 356, 361, 414–415
- PIM-1, 414
- Pin1, 104–105
- Plasmacytoma (PCT), genomic instability, 271–273
- Pluripotency  
   *Drosophila* Myc studies, 183–184  
   establishment, 174–175  
   microRNA role and MYC interactions  
     miR-17–92, 143  
     miR-34, 143  
     miR-100, 142–143  
     miR-141, 142

## Index

- Pluripotency (*Continued*)  
miR-200, 142  
miR-290, 141–142  
miR-371, 142–143  
miR-429, 200  
overview, 141–142  
MYC and MYCN redundancy in early embryonic development, 169–170  
neuroblastoma and MYCN, 356–357  
prospects for study, 145  
stem cell maintenance by MYC, 170–172  
transcriptional regulation complexity of MYC, 172–174
- POLH, 397  
Polycomb-group proteins, 186  
Polycomb repression complex (PRC), 380–383  
Pontin, 185  
PP2A, 415  
inhibitors for MYC therapeutic targeting, 111  
signaling and MYC stability in cancer, 110–111  
PPAR receptors, 227, 234  
PRC. *See* Polycomb repression complex  
PRDX3, 225, 275  
Prolyl hydroxylase, 248  
Prostate cancer, MYC expression and cancer risk, 378–379  
P-TEFb, 28–29, 32, 34, 80–83, 131, 154–155, 210, 361, 393  
PTEN, 30, 39, 145, 330, 381–383  
PTPN11, 364  
PTPRD, 362–364  
PUMA, 261  
PVT1, 375, 377, 379  
Pyruvate dehydrogenase (PDH), 211  
Pyruvate kinase, 214
- R**
- Rac1, 363  
RAD21, 162, 397  
RAD51, 275  
RAS, 30, 311, 359  
RecQ3, 290  
RecQL4, 299  
REDD1, 245  
REEV1L, 397  
RelA, 81  
Replication stress. *See* DNA replication  
REX-1, 356  
RFC4, 131  
RhoA, 94  
Ribonucleotide reductase, 270, 274  
Ribosome  
RNA polymerases in biogenesis. *See* RNA polymerase I; RNA polymerase III  
MYC role in biogenesis and rRNA levels, 118  
Rif1, 292–293  
RNA interference. *See* Synthetic lethal screen  
RNA polymerase I  
MAX network regulation, 123–124  
MYC effects, 118–121  
ribosome biogenesis role, 117–118  
tumorigenesis studies, 125  
upregulation and cell growth, 124–125  
RNA polymerase II  
MYC activation, 28–29, 40, 52, 84, 155  
pause release, 81–82  
transcription initiation, 79–80, 410  
RNA polymerase III  
MAX network regulation, 123–124  
MYC effects, 121–123  
ribosome biogenesis role, 117–118  
tumorigenesis studies, 125  
upregulation and cell growth, 124–125  
Rpl24, 194–195
- S**
- S6K, 188  
SAE1, 396–397  
SAE2, 396–397  
Scrib, 202  
SET, 111  
Sgg, 188  
SHH. *See* Sonic Hedgehog  
SHMT2, 132, 226  
SIRT1, 108, 359, 361  
SIRT2, 107  
Skin papilloma, MIZ-1 mouse model, 96  
SKP2, 29–30, 38, 357, 408  
Skp2, 105–106, 110  
SLC7A5, 211  
Sld2, 290–291  
Sld3, 290–291  
Smads, 209  
SMC1, 162  
SMC3, 162  
Sonic Hedgehog (SHH), 335, 337–339, 344  
SOX2, 174  
Sox2, 141  
SP1, 38–39  
SREBP, 216  
STAT, 198  
STAT3, 170–171  
Stem cell. *See* Pluripotency  
SURF-1, 225  
SUZ12, 172  
SWI/SNF, MYC interactions, 28, 64, 361  
Synthetic lethal screen  
kinase and developmental pathway identification, 398  
MYC-synthetic lethal genes and cancer challenges  
conservation of mechanisms across cancer types, 400



- MYC-driven cancer identification, 399–400
    - specificity in context of cancer genome, 400
    - therapeutic application, 400–401, 415–416
  - DNA repair, cell cycle, and checkpoints, 396–397
  - gene networks, 392
  - growth, metabolism, and apoptosis, 397–398
  - hallmarks, 391–392
  - limitations of study, 391
  - synthetic dosage lethality activators and repressors linked to MYC–MAX, 396
  - transcription initiation and elongation complexes, 392–393, 395–396
  - principles, 387–391
  - yeast genetic networks, 388–389
- T**
- TBB, 64, 120, 122, 393
  - TCA cycle, 211–217, 227, 235, 247
  - TCE, 70, 186
  - TCF-3, 326–331
  - TCF-4, 376–378
  - Telomerase reverse transcriptase (TERT), 29, 364
  - TERT. *See* Telomerase reverse transcriptase
  - TET, 248
  - TFAM, 275
  - TFIID, 82
  - TFIIH, 64, 155, 413
  - TFIIS, 80, 82
  - TFIIB, 121–125
  - TFIIC, 121–123, 125
  - THBS1, 141
  - Thickvein, 200–201
  - TIAM1, 363
  - TIF-1A, 185
  - TIP48, 27
  - TIP49, 27
  - TIP60, 27–28, 35, 407, 410, 415, 297
  - TopBP1, 290, 292
  - TP53INP1, 357
  - Transferrin receptor, 217
  - Transforming growth factor- $\beta$  (TGF- $\beta$ ), 141, 200–201
  - Treslin/Ticrr, 290, 293
  - TRIM32, 107, 188
  - Tristetraprolin (TTP), 65
  - TRKA, 357
  - TRKB, 357
  - TRRAP, 27–29, 34, 52, 120–122, 172, 392, 396, 407, 411–412
  - TRUSS, 106, 110
  - TTP. *See* Tristetraprolin
  - TXNIP
    - functional overview, 245–246
    - glutamine-dependent repression, 247–248
    - MondoA: MLX circuit
    - metabolic reprogramming in G<sub>1</sub> inactivation, 250–251
    - negative feedback loop, 245–247
    - tumor suppression studies, 248–250
    - prospects for study, 252
- U**
- UBE1, 118
  - Ubiquitination, MYC
    - acetylation interplay, 108
    - overview, 102–103
    - regulators, 103–108
    - stability in cancer, 109–111
    - transcriptional activation linkage, 109
  - Upd2, 183
  - Usp28, 105
- V**
- VACTERL, 162
  - Vascular endothelial growth factor (VEGF), 139
  - VEGF. *See* Vascular endothelial growth factor
  - Vertebrate development, MYC function
    - cell fate amplification, 160–162
    - disorders, 162
    - dose-dependent control of embryonic development, 155–158
    - MYCN coordinated action in lineage development and proliferative expansion, 158–160, 169–170
    - overview, 153–154
    - posterior fossa development, 341–343
    - prospects for study, 162–163
    - target genes, 155–156
    - transcriptional control, 154–155
  - v-myc*, 2–3, 129, 209
  - VP16, 30
- W**
- Warburg effect, 137
  - WEE1, 397
  - WEE2, 397
  - Wg, 186–187
  - WNT, 335, 337, 343, 376, 414
  - WRN, 295–297, 397
- Y**
- Yap, 197
  - Yorkie/Yki, 187, 197, 202
  - YY1, 64, 225, 379
- Z**
- Zeb-1, 140–141
  - Zeb-2, 140

This is a free sample of content from MYC and the Pathway to Cancer. [Click here](#) for more information on how to buy the book.